Skip to main content
Clinical Trials/NCT04597788
NCT04597788
Unknown
Not Applicable

The Role of Protein Supplemented Very Low Calorie Medical Meals on Weight and Metabolic Changes Among People With Obesity: a Randomized Controlled Trial

Seoul National University Hospital1 site in 1 country104 target enrollmentNovember 16, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
Seoul National University Hospital
Enrollment
104
Locations
1
Primary Endpoint
Changes in weight
Last Updated
5 years ago

Overview

Brief Summary

This randomized clinical trial will evaluate the efficacy and safety of protein supplemented very low calorie meals on weight loss and weight loss maintenance among people with obesity.

Detailed Description

Approximately 30% of the Korean population has obesity or abdominal obesity and is often accompanied by obesity related complications such as cardiovascular disease, diabetes, osteoarthritis and even some types of cancer. However, there are not many lifestyle modification treatments available that have long-term effects other than drugs and surgical treatments in the management of obesity. Preserving muscle mass should also be considered in weight loss especially for elderly adults with obesity, because decreased muscle mass and strength can negatively affect morbidity and mortality in the elderly. Therefore, the investigators want to evaluate the effectiveness and safety of the protein supplemented very low calorie meals on weight loss, body composition as well as metabolic changes compared with traditional low calorie low fat diet in people with obesity.

Registry
clinicaltrials.gov
Start Date
November 16, 2020
End Date
January 31, 2023
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Body Mass Index (BMI ) more than 25 kg/m2 or
  • Waist circumference more than 90 cm in men or 85 cm in women

Exclusion Criteria

  • History of treatment with anti-obesity drugs or participation in another weight loss program in previous 6 months
  • Weight changes more than 3 kg during the 6 months before participation
  • Unstable cardiovascular events during the 6 months before participation
  • Uncontrolled mood disorder
  • History of eating disorder
  • History of alcohol use disorder
  • History of gallstone
  • Chronic renal failure (estimated glomerular filtration less than 30 ml/min)

Outcomes

Primary Outcomes

Changes in weight

Time Frame: 12 months

Changes of weight loss from the baseline expressed as kg

Secondary Outcomes

  • Changes in systolic and diastolic blood pressure(12 months)
  • Changes in glucose(12 months)
  • Changes in triglyceride(12 months)
  • Changes in high density lipoprotein (HDL) Cholesterol(12 months)
  • Changes in body composition(12 months)
  • Changes in liver enzyme(12 months)
  • Changes in insulin resistance(12 months)
  • Changes in low density lipoprotein (LDL) Cholesterol(12 months)
  • Changes in obesity related quality of life(12 months)

Study Sites (1)

Loading locations...

Similar Trials